Therapeutic Anticoagulation in Non-Critically Ill Patients with Covid-19

‘We adopted a novel prospective mpRCT design, whereby three collaborating platforms developed and administered harmonized trial protocols across complementary global networks of sites to increase efficiency and reliability of evidence’

REMAP-CAP, a trial in Spiral’s study manifest, has recently been integrated into a multiplatform randomised controlled trial (mpRCT).

The results have proven that therapeutic-dose anticoagulation with heparin increases the probability of survival for those hospitalized as non-critically ill patients with Covid-19.

An incredible outcome showing the power of combining multiple trials for faster results!

Read the full report here.

Source: medRxiv